Riskpilot← Back to searchSign inGet full accessRanger Biotechnologies A/S
A/SActiveCVR 32280404C.F. Tietgens Boulevard 30A, st. thResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20091 employeesrangerbiotechnologies.com
Revenue 2024
DKK -224K
-114% vs 2023
EBITDA margin
157.4%
-121% vs 2023
Equity ratio
97.2%
Financial strength
Net profit 2024
DKK -1,1M
-180% vs 2023
| Revenue | DKK -224K | -114% |
| EBITDA | DKK -352K | -121% |
| Net profit | DKK -1,1M | -180% |
| Total assets | DKK 1,6M | -42% |
| Equity | DKK 1,6M | -42% |
| Employees | 1 | — |
Legal name
Ranger Biotechnologies A/S
CVR number
32280404
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. juli 2009
Share capital
DKK 9.414.789
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et bestyrelsesformand sammen med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at eje, skabe og forvalte immaterielle rettigheder samt hermed beslægtede aktiviteter.
Address
C.F. Tietgens Boulevard 30A, st. th
Phone
+4553623170
Email
info@rangerbiotechnologies.com
Website
rangerbiotechnologies.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2.429 | 5.709 | 7.096 | 1.654 | -224 |
| Staff expenses | -2.422 | -5.386 | -6.069 | -52 | -128 |
| EBITDA | 8 | 323 | 1.027 | 1.706 | -352 |
| Depreciation & amort. | -2 | -195 | -639 | -277 | -792 |
| EBIT | 6 | 128 | 388 | 1.429 | -1.144 |
| Net financials | -6 | -17 | -16 | 3 | 6 |
| Profit before tax | 0 | 111 | 372 | 1.432 | -1.138 |
| Tax | -0 | -61 | -0 | -0 | -0 |
| Net profit | 0 | 172 | 372 | 1.432 | -1.138 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2.243 | 5.668 | 2.682 | 2.778 | 1.599 |
| Equity | 717 | 889 | 1.261 | 2.693 | 1.555 |
| Long-term debt | 0 | 0 | 0 | 13 | 0 |
| Short-term debt | 1.525 | 4.779 | 1.421 | 72 | 44 |
| Total debt | 1.525 | 4.779 | 1.421 | 85 | 44 |
EBITDA margin
-35199300.0%
This company
15.8%
Market median
-222780480% vs market
20202024
Equity ratio
97.2%
This company
38.2%
Market median
+154% vs market
20202024
Return on equity
-73.2%
This company
18.4%
Market median
-498% vs market
20202024
Net profit margin
-113809200.0%
This company
8.1%
Market median
-1405051952% vs market
20202024
Asset turnover
-0.14×
This company
1.12×
Market median
-113% vs market
20202024
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HT Chief Executive Officer | Chief Executive Officer | 2010 |
| Former (1) | ||
PS Chief Executive Officer | Chief Executive Officer | 2009 – 2010 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2018 | |
| Board of Directors | 2018 | |
| Chairman | 2018 | |
| Former (6) | ||
| Chairman | 2017 – 2018 | |
| Board of Directors | 2010 – 2013 | |
| Board of Directors | 2010 – 2018 | |
| Board of Directors | 2009 – 2017 | |
| Chairman | 2010 – 2017 | |
| Board of Directors | 2015 – 2018 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50–66.65% | 50–66.65% | 2018 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2018 | |
| Company | 66.67–89.99% | 66.67–89.99% | 2013 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Outlate Holding ApS
Ranger Biotechnologies A/S Board members of Ranger Biotechnologies A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Thorleif Møller | Chief Executive Officer | 0 companies |
| Palle Schelde Jensen | Chief Executive Officer | 0 companies |
| Søren Tvede Larsen | Board of Directors | 0 companies |
| Jarne Elleholm | Chairman | 0 companies |
| Kasper Tvede Larsen | Board of Directors | 0 companies |
| Ole Bitsch-Jensen | Board of Directors | 0 companies |
| John Riis Mortensen | Board of Directors | 0 companies |
| Finn Cilius Nielsen | Board of Directors | 0 companies |
| Peter Buhl | Chairman | 0 companies |
| Christina Møller Udesen | Chairman | 0 companies |
| Søren Morgenthaler Echwald | Board of Directors | 0 companies |